Morgan Stanley Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $70

Morgan Stanley analyst Sean Laaman has initiated coverage on Enliven Therapeutics (NASDAQ: ELVN) with an Overweight rating. The firm has set a price target of $70 for the company's stock.